News and features

Researchers from the ICR and The Royal Marsden submitted fantastic images to this year’s ICR Science and Medical Imaging competition, with winning images by PhD student Sumana Shrestha showcasing just how captivating scientific and medical images can be.

A tiny molecule of RNA – known as ‘microRNA’ – plays a key role in ‘rewiring’ cancer cells so they can resist the effects of chemotherapy, a new study reveals. The discovery opens up the possibility of creating new cancer drugs that target this microRNA molecule, rather than more conventional treatments that block the action of proteins.

Supercharging the mutation rate in cancer cells can create a powerful vaccine that is able to boost the effectiveness of immunotherapy, a major new study reports.

A new multimillion investment is to drive forward development of The London Cancer Hub – boosting efforts to turn it into the world’s leading life-science campus focused on overcoming cancer.

Oncolytic viruses are viruses which can burst cancer cells. In this feature, Joanne Duffy takes a look at what ICR researchers are doing in this realm, and how oncolytic viruses can help us target cancer more effectively.

A simple test using an MRI scan can be used to predict how well people with advanced ovarian cancer will respond to treatment, according to the results of a new study.

Despite increasing numbers of cancer drugs being licensed, an analysis has found that highly innovative drugs took longer to reach NHS patients than more conventional treatments.

The Science Museum's new £24 million medicine galleries showcases pioneering research from The Institute of Cancer Research, London, as part of its story of modern medicine.

Data from a clinical trial which assessed the benefits of adding chemotherapy alongside radiotherapy for patients with muscle invasive bladder cancer has shown that this treatment can be given without substantially impacting subsequent health related quality of life.

Aggressive, highly mutated cancers evolve escape routes in response to immune attacks in an ‘evolutionary arms race’ between cancer and the immune system, a new study reports.

The ICR has criticised the decision by NICE not to recommend the immunotherapy, pembrolizumab, as a first-line treatment for patients with advanced head and neck cancer and is calling for an urgent reassessment of the evidence for the drug’s benefit.

The Institute of Cancer Research, London, strongly welcomes the recommendation by the Scottish Medicines Consortium (SMC) to make the prostate cancer drug abiraterone available to men with advanced prostate cancer as first-line treatment on the NHS in Scotland.